Sign In
Buy SLS
$8.23
-0.81 (-8.96%)
At Close: Jun 05, 2026
SELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights
08:51pm, Tuesday, 05'th Apr 2022 GlobeNewswire Inc.
– In-licensed Next-Generation, Highly Selective CDK9 Inhibitor –
Solaris Adds to Near Surface, High-Grade Northeast and Southeast Extensions, Priorities for Further Growth Beyond Mineral Resource
11:00am, Monday, 04'th Apr 2022 GlobeNewswire Inc.
VANCOUVER, British Columbia, April 04, 2022 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or “the Company”) is pleased to report assay results from a series
SELLAS Life Sciences Stock Plunges After $25M Capital Raise Via Equity, In-Licenses Cancer-Focused CDK9 Inhibitor
08:58am, Friday, 01'st Apr 2022
GenFleet Therapeutics has granted GFH009 rights to SELLAS Life Sciences Group Inc (NASDAQ: SLS) across all therapeutic and diagnostic uses worldwide outside of Greater China (mainland China, Hong
SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering
01:03am, Friday, 01'st Apr 2022 GlobeNewswire Inc.
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the develo
SELLAS Life Sciences Announces Proposed Underwritten Public Offering
08:11pm, Thursday, 31'st Mar 2022 GlobeNewswire Inc.
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the develo
SELLAS Life Sciences Signs Exclusive License Agreement with GenFleet Therapeutics for Next-Generation, Highly Selective CDK9 Inhibitor
08:08pm, Thursday, 31'st Mar 2022 GlobeNewswire Inc.
- SELLAS In-licenses Worldwide Rights Outside of Greater China for Clinical-Stage Asset -
Solaris and CELEC Announce MOU to Supply Low-Cost, Emission-Free Hydroelectric Power to Warintza
11:00am, Monday, 21'st Mar 2022 GlobeNewswire Inc.
VANCOUVER, British Columbia, March 21, 2022 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) and its subsidiary Lowell Mineral Exploration Ecuador S.A. ("Solaris" or “the Compan
Sellas, Merck complete enrollment in GPS-Keytruda combo phase 1/2 trial in ovarian cancer
08:03pm, Tuesday, 01'st Feb 2022 Seeking Alpha
Sellas Life Sciences <> completed enrollment in a phase 1/2 trial of its lead asset galinpepimut-S ((GPS)) in combination with Mercks <> Keytruda (pembrolizumab) in second
SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer
01:30pm, Tuesday, 01'st Feb 2022 GlobeNewswire Inc.
Joint Development Committee of SELLAS and Merck Agreed on Study Completion and Overall Operational Path Towards Data Analysis
Sellas Life Sciences'' IND application for galinpepimut-S accepted in China
11:07am, Thursday, 27'th Jan 2022 Seeking Alpha
SELLAS Life Sciences Group (SLS) announces that an IND application to initiate the first clinical trial in China for 3D189, also known as galinpepimut-S ((GPS)), has been accepted
SELLAS Life Sciences Announces IND Acceptance for First Clinical Trial of GPS in China
01:00am, Thursday, 27'th Jan 2022 GlobeNewswire Inc.
Chinese Partner, 3D Medicines, Expects to Initiate Trial in Second Half of 2022 in Patients with Hematological Malignancies Who Achieved Objective Response After Receiving Standard Treatment Chinese P
Solaris Announces Significant New Discovery at Warintza South
11:00am, Tuesday, 18'th Jan 2022 GlobeNewswire Inc.
VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce a significant new discovery
SELLAS Life Sciences Promotes John Burns to Senior Vice President, Finance and Chief Accounting Officer
01:30pm, Wednesday, 05'th Jan 2022 GlobeNewswire Inc.
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing
SELLAS Life Sciences Group (TSE:SLS) Hits New 12-Month High Following Analyst Upgrade
04:26pm, Thursday, 16'th Dec 2021 Transcript Daily
SELLAS Life Sciences Group Inc (TSE:SLS)s stock price reached a new 52-week high during trading on Thursday after TD Securities raised their price target on the stock from C$21.00 to C$22.00. TD Securities currently has a speculative buy rating on the stock. SELLAS Life Sciences Group traded as high as C$15.21 and last traded at []
SELLAS Life Sciences Group (TSE:SLS) Stock Price Up 0.5%
05:52am, Thursday, 16'th Dec 2021 Transcript Daily
SELLAS Life Sciences Group Inc (TSE:SLS)s share price was up 0.5% during mid-day trading on Wednesday . The stock traded as high as C$14.24 and last traded at C$14.19. Approximately 361,992 shares changed hands during trading, an increase of 105% from the average daily volume of 176,645 shares. The stock had previously closed at C$14.12. []
